Chinese activists protest the use of traditional treatments - they want medical science

In the West, the number of people challenging scientific authority has been growing in past decades. This has, among other things, led to a decline in the support for mass vaccination programmes and to an increase in alternative forms of treatment. In China, however, activists are defending modern medical science and criticising Traditional Chinese Medicine, which hospitals are obliged to offer to patients on an equal footing with modern medical care.

Over a number of years, Chinese researcher Qiaoyan Zhu, who has been affiliated with the University of Copenhagen's Department of Communication, has collected data on the many thousand science activists in China through observations in Internet forums, on social media and during physical meetings. She has also interviewed hundreds of activists.

Together with Professor Maja Horst, who has specialised in research communication, Zhu has analysed the many data on the activists and their protests in an article that has just been published in the journal Public Understanding of Science:

"The activists are better educated and wealthier than the average Chinese population, and a large majority of them keep up-to-date with scientific developments. The protests do not reflect a broad popular movement, but the activists make an impact with their communication at several different levels," Maja Horst explained and added:

"Many of them are protesting individually by writing directly to family, friends and colleagues who have been treated with - and in some cases taken ill from - Traditional Chinese Medicine. Some have also hung posters in hospitals and other official institutions to draw attention to the dangers of traditional treatments. But most of the activism takes place online, on social media and blogs.

The activists hold the cards

Activists operating in a regime like the Chinese are obviously not given the same leeway as activists in an open democratic society - there are limits to what the authorities are willing to accept in the public sphere in particular. However, there is still ample opportunity to organise and plan actions online.

"In addition to smaller groups and individual activists that have profiles on social media, larger online groups are also being formed, in some cases gaining a high degree of visibility. The card game with 52 criticisms about Traditional Chinese Medicine that a group of activists produced in 37,000 copies and distributed to family, friends and local poker clubs is a good example. Poker is a highly popular pastime in rural China so the critical deck of cards is a creative way of reaching a large audience," Maja Horst said.

Maja Horst and Qiaoyan Zhu have also found examples of more direct action methods, where local activist groups contact school authorities to complain that traditional Chinese medicine is part of the syllabus in schools. Or that activists help patients refuse treatment if they are offered treatment with Traditional Chinese Medicine.

Will we see similar science activism in Europe?

The Chinese style of science activism, which Maja Horst and Qiaoyan Zhu have studied, is rather traditional and fact-based compared to the often more spectacular and symbol-laden communication that Western activists use when, for example, protesting genetic research. But they conclude by anticipating a possible similar development in the West:

"We have already seen Marches for Science in the US and Europe so it is not unlikely we will begin to see more activism in favour of science and evidence-based medicine in our part of the world as well. We may well see a counter-reaction towards climate sceptics and anti-vaxxers who challenge established science and its results."

Qiaoyan Zhu, Maja Horst.
Science communication activism: Protesting Traditional Chinese Medicine in China.
Public Understanding of Science, Volume: 28 issue: 7, page(s): 812-827. doi: 10.1177%2F0963662519865405.

Most Popular Now

AstraZeneca amends collaboration with Ironwood for…

AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong and China Macau for Linzess (linaclo...

Cause of antibiotic resistance identified

Scientists have confirmed for the first time that bacteria can change form to avoid being detected by antibiotics in the human body. Studying samples from elderly patient...

Bayer, Brigham and Women’s Hospital, and Massachus…

Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a joint lab to ...

FDA grants Fast Track designation for Farxiga in h…

AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk ...

Amgen announces positive results from two Phase 3 …

Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (2012021...

Brilinta monotherapy in high-bleeding risk patient…

New data from TWILIGHT, a Phase IV independent trial (funded by AstraZeneca), showed that in patients at high-bleeding risk who underwent PCI and completed 3 months of du...

Gene-targeted cancer drugs, slow release overcome …

Biomedical engineers at Duke University have developed a method to address failures in a promising anti-cancer drug, bringing together tools from genome engineering, prot...

Educational campaign helps teens and their caregiv…

Teenagers face many challenges, and growing up with a chronic skin disease called atopic dermatitis (AD) can impact the ups and downs and transitions to young adulthood. ...

Study points to new drug target in fight against c…

Researchers have identified a potential new drug target in the fight against cancer. In a study this week in the Proceedings of the National Academy of Sciences, an inter...

AstraZeneca divests rights for Losec to Cheplaphar…

AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arznei...

Cheaper drug just as effective protecting heart in…

A new clinical trial conducted at The Ohio State University Wexner Medical Center found a cost-effective generic medication works just as well as a more expensive drug in...

Dengue virus becoming resistant to vaccines and th…

Researchers from Duke-NUS Medical School (DukeNUS), in collaboration with the Agency for Science, Technology and Research (A*STAR)'s Bioinformatics Institute (BII), and t...